CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 170 enrolled
Drug / intervention
SE5-OH tabletsdietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06398236
NCT06398236N/ACompleted

Multicentre, Exploratory, Prospective, Open-labelled, Non-controlled Study to Evaluate the Effect of SE5-OH Tablets on Healthy Women With Menopausal Symptoms

Nutrition & Sante Iberia·interventional·Posted May 3, 2024·Updated Jul 8, 2025

In Brief

A clinical study evaluating SE5-OH tablets for Menopause. Completed, enrolled 170 participants across 1 site.

Detailed Summary

Multicentre, exploratory, prospective, open-labelled study to evaluate the efficacy of SE5-OH tablets on menopausal symptoms in healthy women experiencing menopausal symptoms after 12 weeks of administration. The study will be performed in 10 hospitals (private and public) located in Spain. Recruitment period of 6 months will be defined in order to include up to 300 healthy volunteers from different national hospitals and clinics.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMenopause
CountriesSpain

Timeline

N/ACompletedFinished
202420252026
First PostedMay 3, 2024
Enrollment StartMar 17, 2023
Primary CompletionJul 18, 2024
Study CompletionOct 16, 2024
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 2.2 years ago

Interventions

SE5-OH tabletsdietary

SE5-OH (Fermented Soy germ, include S-equol), Crystalline cellulose, Oats fiber, Agar, Cyclic oligosaccharide, HPMC, Reduced syrup.